MedTrace Logo

Oncological Care for Patients With Meningioma

NCT02973256 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1204

Last updated 2022-04-14

No results posted yet for this study

Summary

Meningiomas with malignant components include grade II meningiomas (GIIM, the most common ones) and grade III meningiomas (GIIIM). They represent 5-35% of all meningiomas. Histological diagnosis of GIIM criteria were changed in 2007 and might be viewed by some as being quite subjective. "Standards of care" and consensus do not exist for GIIM, particularly in regards to performing, or not, radiotherapy after surgery. One other limitation in the literature is lack of data on health-related quality of life (HRQoL). Clinical trials for GIIM are very difficult to conduct. No results have been made available. Here, we propose to study clinical, pathological, radiological and therapeutic factors of an exhaustive population of GIIM and GIIIM patients, at national level. The main objective (for GIIM) is to assess the impact of postoperative radiotherapy, or the absence of postoperative radiotherapy, on overall survival and on quality of life

Conditions

  • Atypical Meningioma
  • Clear-cell Meningioma
  • Chordoid Meningioma
  • Anaplastic Meningioma
  • Rhabdoid Meningioma
  • Papillary Meningioma

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    collaborator OTHER

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • LUC BAUCHET, MD, PhD · UH MONTPELLIER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2023-07-01
Completion
2023-12-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02973256 on ClinicalTrials.gov